WSO December 2023 – Issue 3 - 1200

1200
International Journal of Stroke 18(10)
Acknowledgements
The authors thank all SITS-ISTR investigators and their centers
for their participation. The authors also pass on their thanks to all
patients who participated in SITS-ISTR.
Data availability statement
Access to anonymized SITS-ISTR data will be available from the
corresponding
author on reasonable
request from qualified
researchers and approval by the SITS Scientific Committee.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: N.A. reports that he is chair of SITS International and
received speaker honorarium from Boehringer Ingelheim. S-Y.C.
is an employee of Biogen and owns stock in Biogen. N.T. was an
employee of Biogen at the time of the study and owns stock in
Biogen.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article:
SITS is financed directly and indirectly by grants from Karolinska
Institutet, Stockholm County Council, and the Swedish HeartLung
Foundation as well as from an unrestricted sponsorship
from Boehringer Ingelheim. SITS has previously received grants
from the European Union Framework 7, the European Union
Public Health Authority and Ferrer International and EVER
Pharma. SITS is currently conducting studies supported by
Boehringer Ingelheim. SITS has previously conducted study
supported by Stryker, Covidien and Phenox in collaboration
with Karolinska Institutet. M.T. has received grants or funding
from Stiftelsen Tornspiran, Stiftelsen Sigurd och Elsa Goljes
Minne, STROKE-Riksförbundet, Capio forskningsstiftelse, and
Karolinska University Hospital. I.E-M. has received a grant from
" Fundación Progreso y Salud, Junta de Andalucía " (grant
EF-0437-2018). N.A. received grants from Stockholm County
Council and the Swedish Heart-Lung Foundation. This study was
sponsored by Biogen. Other funding sources had no part in the
design and conduct of the study; collection, management, analysis,
and interpretation of the data; or preparation, review, or
approval of the manuscript; or the decision to submit the manuscript
for publication.
ORCID iDs
Magnus Thorén
Simone Beretta
Andre Peeters
https://orcid.org/0000-0002-8216-9066
Irene Escudero-Martínez
0235
Georgios Tsivgoulis
https://orcid.org/0000-0003-1838https://orcid.org/0000-0002-9417-2748
https://orcid.org/0000-0001-9989-4283
https://orcid.org/0000-0002-0640-3797
Supplemental
material
Supplemental material for this article is available online.
References
1. Battey TW, Karki M, Singhal AB, et al. Brain edema predicts
outcome after nonlacunar ischemic stroke. Stroke 2014; 45:
3643-3648.
2. Stokum JA, Gerzanich V and Simard JM. Molecular pathophysiology
of cerebral edema. J Cereb Blood Flow Metab
2016; 36: 513-538.
3. Escudero-Martínez I, Thorén M, Ringleb P, et al. Cerebral
edema in patients with severe hemispheric syndrome: incidence,
risk factors, and outcomes-data from SITS-ISTR.
Stroke 2023; 25: 101-110.
4. Thorén M, Azevedo E, Dawson J, et al. Predictors for cerebral
edema in acute ischemic stroke treated with intravenous
thrombolysis. Stroke 2017; 48: 2464-2471.
5. Huttner HB and Schwab S. Malignant middle cerebral artery
infarction: clinical characteristics, treatment strategies, and
future perspectives. Lancet Neurol 2009; 8: 949-958.
6. Qureshi AI, Suarez JI, Yahia AM, et al. Timing of neurologic
deterioration in massive middle cerebral artery infarction: a
multicenter review. Crit Care Med 2003; 31: 272-277.
7. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M and
von Kummer R. " Malignant " middle cerebral artery territory
infarction: clinical course and prognostic signs. Arch Neurol
1996; 53: 309-315.
8. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive
surgery in malignant infarction of the middle cerebral artery:
a pooled analysis of three randomised controlled trials. Lancet
Neurol 2007; 6: 215-222.
9. Khatri R, McKinney AM, Swenson B and Janardhan V.
Blood-brain barrier, reperfusion injury, and hemorrhagic
transformation in acute ischemic stroke. Neurology 2012; 79:
S52-S57.
10. Bai J and Lyden PD. Revisiting cerebral postischemic reperfusion
injury: new insights in understanding reperfusion failure,
hemorrhage, and edema. Int J Stroke 2015; 10: 143-152.
11. Irvine HJ, Ostwaldt AC, Bevers MB, et al. Reperfusion after
ischemic stroke is associated with reduced brain edema. J
Cereb Blood Flow Metab 2018; 38: 1807-1817.
12. Kimberly WT, Dutra BG, Boers AMM, et al. Association of
reperfusion with brain edema in patients with acute ischemic
stroke: a secondary analysis of the MR CLEAN trial. JAMA
Neurol 2018; 75: 453-461.
13. Huang X, Yang Q, Shi X, Xu X, Ge L, Ding X and Zhou
Z. Predictors of malignant brain edema after mechanical
thrombectomy for acute ischemic stroke. J Neurointerv Surg
2019; 11: 994-998.
14. Ng FC, Yassi N, Sharma G, et al. Cerebral edema in patients
with large hemispheric infarct undergoing reperfusion treatment:
a HERMES meta-analysis. Stroke 2022; 53: 2628-
2636.
15. Thoren M, Dixit A, Escudero-Martinez I, et al. Effect of recanalization
on cerebral edema in ischemic stroke treated with
thrombolysis and/or endovascular therapy. Stroke 2020; 51:
216-223.
16. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with
alteplase for acute ischaemic stroke in the Safe Implementation
of Thrombolysis in Stroke-Monitoring Study (SITS-MOST):
an observational study. Lancet 2007; 369: 275-282.
International Journal of Stroke, 18(10)
https://www.orcid.org/0000-0002-8216-9066 https://www.orcid.org/0000-0003-1838 https://www.orcid.org/0000-0002-9417-2748 https://www.orcid.org/0000-0001-9989-4283 https://www.orcid.org/0000-0002-0640-3797
WSO December 2023 – Issue 3

Table of Contents for the Digital Edition of WSO December 2023 – Issue 3
